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Abstract The main objective of this study is to assess the
feasibility of transoral laser microsurgery (TLM) in the
treatment of T4a laryngeal cancer and to report the onco-
logical and functional outcomes. This is a retrospective case-
series study, held in a single-institute, academic tertiary
referral center. Seventy-nine patients with previously
untreated T4a glottic (n = 31, 39 %) or supraglottic lar-
yngeal carcinoma (n = 48, 61 %) were included in this
study. Five patients (6 %) were treated exclusively by TLM,
16 (20 %) had TLM and unilateral neck dissection, 27 (35 %)
had TLM and bilateral neck dissection. Adjuvant
(chemo)radiotherapy was additionally administered in 26
(33 %) cases following TLM and neck dissection, and in 5
(6 %) cases after TLM without neck dissection. The main
outcome measures included organ preservation, local control,
functional outcome, overall, recurrence-free, and disease-
specific survival. The median follow-up period was
49 months, 5 year organ preservation rate and local control
rate were 80.0 and 67.2 %, 5 year overall, recurrence-free
and disease-specific survival were 55.8, 61.9 and 71.8 %. The
5 year overall survival rates were 62.5 % in pN0 cases and
57.2 % in cases with pN-positive neck disease. With respect
to survival, these results are comparable to total laryngec-
tomy, while being superior to primary (chemo)radiotherapy.
TLM results in a low morbidity, rapid recovery and good
function and can be a valid option for organ preserving sur-
gery of pT4a glottic and supraglottic cancer.
Keywords T4 laryngeal carcinoma  Transoral laser
microsurgery  Oncologic results  Functional outcomes
Introduction
Malignant tumors of the head and neck represent 6.6 % of
all tumors registered by the American Cancer Society, with
laryngeal cancer accounting for almost 21 % [1]. While the
incidence and mortality of laryngeal cancer seems to
decline [2], no significant improvements regarding overall
survival of advanced laryngeal cancer have been achieved
in the last three decades.
After the introduction of the CO2 laser for the treatment
of benign and very early malignant laryngeal lesions by
Jako and Strong [3], Steiner expanded the indications of
transoral laser microsurgery (TLM) to all tumor categories
of the upper aero-digestive tract [4–7] in the early 1980s.
Using TLM, it is possible to minimize the loss of
healthy tissue, to avoid extensive reconstruction proce-
dures, and primary tracheotomies in most cases and to
lower the overall morbidity. This method can be seamlessly
integrated into any therapeutic regimen while maintaining
all salvage treatment options. Prerequisites for using this
TLM are a detailed knowledge of endoscopic anatomy,
microsurgery and proficiency in the use of lasers.
The aim of the present study was to evaluate the
oncologic and functional outcome of TLM for T4a glottic
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and supraglottic cancer and to prove the validity of this
treatment method by comparing it to total laryngectomy or
primary (chemo)radiotherapy as current standard of care.
Patients and methods
Between August 1987 and December 2006, a total of 79
patients with pT4a glottic and supraglottic laryngeal
squamous cell carcinoma were treated with curative intent
at the Department for Otorhinolaryngology—Head and
Neck Surgery, University of Go¨ttingen.
Previously untreated tumors were staged according to
the current classification of the Union for International
Cancer Control (UICC) and the American Joint Committee
on Cancer (AJCC) [8]. We included moderately advanced
tumors that invaded through the thyroid cartilage and/or
soft tissues of the neck. Exclusion criteria for this study
were: non-squamous cell carcinoma tumors, simultaneous
second primary or distant metastases, and N3 neck disease.
All patients were exclusively treated by TLM. Open sur-
gery procedures were excluded. Further exclusion criteria
were bilateral arytenoid fixation and deep infiltration of the
neck by the primary tumor with involvement of the carotid
artery.
Of 176 patients with a T4a laryngeal cancer presenting
for treatment in our hospital, 97 had to be excluded. The
reasons were: (a) treatment without TLM in 35 cases (open
surgery in three cases, total laryngectomy in three patients,
13 cases were treated primarily by (chemo)radiotherapy
and palliative treatment in 16 cases); (b) treatment with
TLM but exclusion due to exclusion criteria in 62 cases (20
patients with recurrent or residual disease after primary
treatment elsewhere, previous treatment for cancer in the
upper aero-digestive tract (eight patients) or simultaneous
second primaries (eight patients), 26 patients were exclu-
ded because of N3 neck disease, non-SCC histology,
simultaneous distant metastases or death before therapy.)
A total of 79 patients fulfilled the inclusion criteria and
were statistically analyzed of which, 69 male (87 %) and
10 female (13 %), 31 patients with glottic (39 %) and 48
patients with supraglottic laryngeal carcinoma (61 %). The
age ranged from 32 to 80 years the median age being
57 years.
Preoperative examination
Preoperatively, all patients underwent rigid or flexible
endoscopic examination of the oral cavity, pharynx and
larynx whilst awake. This was followed by sonography of
the neck.
Patients initially mainly underwent CT scanning of the
neck while later MRI was added when deemed necessary.
Standard diagnostics included X-ray examination of the
chest and sonography of the abdomen. Panendoscopy was
performed under general anesthesia at the beginning of the
surgical procedure with the intention to exclude any second
primary tumor in the aero- and upper digestive tract fol-
lowed by laser biopsy if the carcinoma was not yet proven
by histology.
Treatment of the primary tumor
The surgical procedures were performed under general
anesthesia and with orotracheal intubation. Different closed
or distending laryngoscopes (Karl Storz, Tuttlingen,
Germany) were used for adequate exposure of the tumor.
Depending on localization and size of the tumor, the
endotracheal tube was placed above the upper blade of the
laryngoscope if exposure of the posterior commissure was
required. Occasionally, the endotracheal tube had to be
removed temporarily to resect subglottic or tracheal tumor
spread in apnea. As good exposure and visualization are
prerequisites of a safe and successful resection, the lar-
yngo-pharyngoscope sometimes had to be repositioned
several times during the operation. To remove laser plume,
the laryngo-pharyngoscopes were equipped with integrated
suction tubes.
Tumors were excised in a step-wise fashion with spe-
cific blocks of tumor being consecutively removed. In
contrast to the open classic en-bloc resection, the tumor
was resected endoscopically in a step-by-step procedure
under microscopic magnification using CO2 laser in con-
tinuous superpulse mode [9]. Hereby, the surgeon follows
the tumor, while preserving as much as possible healthy
and functionally important tissue. The specific tissue cut-
ting characteristics of the CO2 laser helps the surgeon to
differentiate between healthy tissue and tumor. Steiner [6]
introduced this unconventional technique in the early
1980s showing that cutting through the tumor is necessary
and justified, because the lymphatic vessels of the wound
margins are sealed immediately, as shown by Werner et al.
[10].
Tumor was resected under the microscope with surgical
resection margins in healthy tissue from 2 to 3 mm (glottis)
or 5 to 10 mm (supraglottis). As the quality of the post-
operative function depends directly on the extent of the
resection, it was our goal to preserve as much healthy
laryngeal tissue as possible. If the histopathological anal-
ysis of the resected specimens by frozen sections showed a
positive resection margin, an additional resection was
carried out to obtain negative margins until an adequate
distance between the margin of the tumor and the resection
borders was achieved. However, the number of analyzed
frozen sections depended on the experience of the surgeon
and of the localization and extent of the tumor.
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Tumors that extended to the paraglottic space required
resection that reached laterally to the thyroid cartilage and
caudally to the cricoid cartilage. If necessary, the arytenoid
cartilage and/or parts of the thyroid or cricoid cartilage and
extralaryngeal tissue were included in the endoscopic
resection.
We used a CO2 laser system to perform the surgical
procedures (40c, Lumenis, Dreieich, Germany). It was
equipped with a micromanipulator attached to the operating
microscope (OPMI Vario/S88, Zeiss, Go¨ttingen, Germany).
The focus diameter of the micromanipulator was 0.5 and
0.25 mm, respectively; approximately 2,080–3,900 W/cm2
of laser energy were transmitted. The amount of laser power
used varied from 3 W for subtle resections to 15 W when
cutting through a large tumor mass. This administered laser
power was able to coagulate vessels with a maximum
diameter of 0.5 mm. Larger vessels were coagulated with
mono- or bipolar forceps. Vascular clips were applied to the
superior artery and branches. If considerable portions of
cartilage were exposed or partially removed during resec-
tion of the tumor, we administered antibiotics periopera-
tively to avoid perichondritis. Duration of surgery depended
on the localization and the extent of the tumor, exposure of
the surgical site and experience of the surgeon. Mean
duration was 2–3 h extending up to 5 h when small closed
laser laryngoscopes had to be used for better exposure of the
tumor.
Treatment of the neck
Neck dissections were mainly selective (N0–N2) and
usually performed as a delayed procedure after initial
TLM. Delayed neck dissection could be combined with a
second microlaryngoscopic exploration if the pathology
report after initial TLM indicated that this was advisable.
Adjuvant (chemo)radiotherapy
Adjuvant (chemo)radiotherapy was performed in cases of
N2 neck disease or when the histopathological examination
revealed lymphangiosis carcinomatosa and/or extracapsu-
lar tumor spread. If it was impossible to prove all margins
we recommended adjuvant treatment to the patients inde-
pendent of neck disease. (Chemo)radiation always was
administered to both the larynx and the neck. Overall 31
patients received radiation, concomitant chemotherapy was
given in 11 cases.
Statistical methods
All survival rates were calculated using the Kaplan–Meier
method. The assessed endpoints were overall, recurrence-
free, and disease-specific survival, local and loco-regional
control, distant metastases and second primaries.
Overall survival was calculated on deaths from all
possible causes, disease-specific survival on deaths from
laryngeal cancer. For calculating recurrence-free survival,
intercurrent deaths and deaths due to secondary primary
tumors as well as patients alive without recurrences were
regarded as censored observations. Events included local
and regional recurrences, distant, recurrent and late
metastases and deaths due to disease. For the calculation of
local control rate, only local recurrences were considered
as events while patients alive without local recurrence or
death regardless of reason were counted as censored
observations. The definition of local recurrence included
carcinoma in situ as well as carcinoma occurring after
completion of primary treatment. Survival times were
calculated from the day of surgery to the date of the
occurrence of the event or the date of the last follow-up.
Results
Oncologic results
Five patients (6 %) were treated exclusively by TLM, 16
(20 %) had TLM and unilateral neck dissection, 27 (35 %)
had TLM and bilateral neck dissection. Adjuvant
radio(chemo)therapy was administered in 26 (33 %) cases
following TLM and neck dissection, and in 5 (6 %) cases
after TLM without neck dissection.
Selective neck dissection (level II/III) was performed in
69 patients (87 %), 52 patients (75 %) were treated bilat-
erally, 17 (25 %) were treated unilaterally to the primary
tumor site. In addition, level I was dissected in eight
patients, level IV in six patients and level V in three
patients. A bilateral modified radical neck dissection (level
I–V) was done in three cases.
Local and loco-regional control
10 of 31 (32 %) patients with pT4a glottic carcinoma
developed local or loco-regional recurrence. Salvage ther-
apy consisted of TLM with adjuvant radiotherapy (n = 3)
or revision neck dissection followed by radiotherapy of the
larynx and the neck (n = 2). Total laryngectomy was
necessary in five cases.
Local or loco-regional recurrence was observed in 13 of
48 (27 %) patients with supraglottic cancer. Salvage ther-
apy consisted of TLM with adjuvant radiotherapy (n = 2)
or revision neck dissection followed by radiotherapy of the
larynx and the neck (n = 2). Total laryngectomy was not
avoidable in nine cases. rpT categories of the first local and
loco-regional recurrence of 23 patients are given in
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Table 1. Table 2 gives patterns of TNM-related treatment
failures after initial therapy.
These absolute figures translate into 2- and 5-year local
control Kaplan–Meier estimates for TLM in T4a laryngeal
cancer of 70.5 and 67.2 %, respectively. Calculated for
glottic and supraglottic laryngeal cancer separately, the
5-year local control was 66.6, and 67.3 %, respectively.
Local control rates for glottic and supraglottic carcinomas are
given in Fig. 1.
Sixteen patients underwent total laryngectomy, due to
oncological (n = 14) or functional reasons (n = 2) calcu-
lating 5-year organ preservation rate of 80 %.
Second primary tumors
Second primary tumors were observed in 10 patients (16 %).
In six of these patients, the second primary tumor was
localized in the head and neck region; in four patients second
primary occurred in the lung (n = 2), GI-tract (n = 2). The
second primary tumors were diagnosed between 6 and
122 months (mean 36 months) after laser resection.
Survival
Kaplan–Meier estimates for 2- and 5-year overall survival,
recurrence-free and disease-specific survival were 81.8 and
55.8%, 67.0 and 61.9 % and 86.5 and 71.8 %, respectively
(Fig. 2a, b, c). If regarding glottic and supraglottic
laryngeal carcinomas 5-year overall, recurrence-free and
disease-specific survival were 65.3, 62.2, 75.4 % and 49.9,
61.6, 69.2 %. If pN-status was taken into account, the
2- and 5-year overall survival rate for pN0 patients were
86.4 and 62.5 % and 75.0 and 57.2 % for pN-positive
patients (Fig. 3). The same effect was observable when
evaluating the 2- and 5-year recurrence-free and disease-
specific survival: 2- and 5-year recurrence-free survival for
pN0 patients were 61.7 % each; for pN-positive patients it
was 73.7 and 68.0 %. 2- and 5-year disease-specific sur-
vival for pN0 patients were 94.4 and 79.9 % and 75.0 and
64.9 % for pN-positive patients (Fig. 4a, b). A total of 41
patients (52 %) died. 19 (46 %) of these 41 patients died of
TNM-related disease, 7 (17 %) died because of second
primaries and 15 of 41 (37 %) intercurrently.
Adjuvant (chemo)radiotherapy, recurrence rate
and salvage treatment
Of 31 patients with glottic cancer, 12 received adjuvant
(chemo)radiotherapy. Eight of 19 patients without adjuvant
treatment developed tumor recurrence after an average
timespan of 11.9 months. Six patients had local recurrence
only. Three of them received local salvage surgery, one
patient salvage laryngectomy and two patients local salvage
Table 1 rpT categories of all 23 first local and loco-regional
recurrences
rpT No. [%]












Table 2 Treatment of first failures after initial therapy depending on T-category
pT4 No. Loc. rec. no. Locoreg. rec. No. Late metastasis no. Rec. metastasis no. R
Glottic 31 9 (29 %) 1 (3 %) 1 (3 %) 0 11
Supraglottic 48 12 (25 %) 1 (2 %) 1 (2 %) 2 (4 %) 16
Fig. 1 Glottic versus supraglottic laryngeal cancer. Local control rate
for 79 patients with T4 primary tumor
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surgery with adjuvant treatment. One patient with loco-
regional recurrence received salvage laryngectomy. Four of
the seven patients with salvage treatment died from the
disease within an average of 20.9 months after recurrence.
Three patients after salvage treatment were still alive
without tumor after 42.1 months. One patient with regional
and distant recurrence received palliative treatment only.
Five of 12 patients with glottic cancer and adjuvant
treatment developed recurrence after an average of
12.2 months. One patient with local recurrence was treated
with salvage laryngectomy and was still alive after a fol-
low-up period of more than 72 months. Another patient
with local recurrence died from disease-related causes
11 months after salvage laryngectomy. Three patients
received palliative care due to distant or extensive local
and regional recurrence.
After transoral laser microsurgery for supraglottic
tumors (n = 48), 19 patients received adjuvant therapy.
Twelve of 29 patients without adjuvant treatment devel-
oped tumor recurrence after an average of 8.8 months.
Local recurrence occurred in nine patients and was treated
by local salvage surgery in two, by salvage laryngectomy
in six and by radiation alone in one case. Salvage treatment
was successful in five patients, who were free of disease for
an average follow-up period of 52.4 months. One patient
with extensive nodal recurrence was treated by radiation
only and died in the aftermath of a further regional and
distant recurrence 29 months later. Two patients with dis-
tant metastases 3 and 5 months after primary treatment
received palliative care only and passed away several
months later.
Six of 19 patients with supraglottic cancer after TLM
and adjuvant therapy developed recurrence. Three cases
were local only and treated by local salvage surgery in 1
occasion and salvage laryngectomy in two. One patient was
still free from tumor 62 months after salvage treatment,
Fig. 2 79 patients with T4 laryngeal cancer. a Overall survival rate. b Recurrence-free survival rate. c Disease-specific survival rate
Eur Arch Otorhinolaryngol (2013) 270:2719–2727 2723
123
two died from disease-specific causes after 14 and
29 months, respectively. Three patients were treated with
palliative care only due to distant metastases or extensive
local and regional recurrence and survived for an average
of 11.2 months.
Postoperative complications and functional results
Postoperative laryngeal bleeding occurred in 2 out of 31
patients presenting with glottic carcinoma (6 %) and in 5 of
48 supraglottic (10 %) cases requiring coagulation and/or
clipping in the operating room under general anesthesia.
Four patients with glottic carcinoma (8 %) needed a
temporary tracheotomy, two intraoperatively at the end of
the resection of the primary tumor as a prophylactic mea-
sure, one due to postoperative bleeding, and one due to
laryngeal edema. In the supraglottic group, 9 of 48 (19 %)
patients underwent a tracheotomy temporary (n = 5) or
permanent (n = 4): five intraoperatively at the end of the
surgical procedure, one because of persistent postoperative
edema, one because of postradiogenic swelling of soft
tissue and two because of persistent aspiration. One patient
suffered a cardiac arrest during surgery that was solved
successfully by the anesthesiologist.
Two patients (3 %) out of 79 (all with supraglottic
cancer) needed total laryngectomy because of functional
reasons and another two patients showed therapy related
pneumonia due of aspiration.
Twenty-two of 31 patients (71 %) in the glottic carci-
noma group needed temporary placement of a nasogastric
feeding tube, which was removed in all but one case within
2 weeks. No gastrostomy tube was needed.
Forty out of 48 patients (83 %) with supraglottic cancer
required a nasogastric feeding tube, which was removed
within 4 weeks in 30 cases (73 %). In four cases (8 %) a
permanent gastrostomy tube had to be placed.
Discussion
The use of transoral laser microsurgery has been interna-
tionally accepted as a valid treatment option for early
Fig. 3 pN0 versus pN?. Overall survival rate for 79 patients with T4
laryngeal cancer
Fig. 4 pN0 versus pN? for 79 patients with T4 laryngeal cancer.
a Recurrence-free survival rate. b Disease-specific survival rate
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laryngeal cancer, however, its use in advanced laryngeal
disease remains still controversial. In our series, we
observed a 5-year local control of 67.2 % for pT4a lar-
yngeal tumors. The 5-year larynx preservation rate was
80 %, 5-year overall, recurrence-free, and disease-specific
survival rate was 55.8, 61.9, 71.8 %. Nonetheless, any
discussion of oncologic outcomes is challenging and can be
descriptive only, since evaluation of the evidence sup-
porting the effectiveness of one treatment over the other is
complicated by different stages, outcome measures, use of
statistics and investigation of different laryngeal sites
(supraglottic vs. glottic vs. all sites).
Total laryngectomy as primary or salvage therapy, dif-
ferent regimens of (chemo)radiotherapy and—in highly
selected cases—open partial laryngectomy are the principal
and widely used standard therapeutic options in many
countries. Unfortunately, despite new therapeutic strategies
like neoadjuvant chemotherapy and improved concomitant
(chemo)radiotherapy procedures, survival rates have not
improved within the last decades. Hoffman et al. [11]
found decreased survival rates among patients with lar-
yngeal cancer during the past two decades in the United
States. In a large review of the National Cancer Data Base,
the authors investigated data of 158,426 patients with lar-
yngeal cancer. During this time there has been an increase
in the non-surgical treatment of laryngeal cancer. Espe-
cially for advanced laryngeal cancer, 5-year observed and
relative survival showed the best outcome for patients
whose initial management was surgery either alone or
combined with irradiation.
Few data have been published concerning primary sur-
gical therapy in T4 laryngeal cancer. Ampil et al. [12]
reported on 28 patients with T4 laryngeal cancer treated by
total laryngectomy and postoperative radiotherapy. Kada
et al. [13] investigated 33 patients with advanced T3/T4
laryngeal squamous cell carcinoma after total laryngec-
tomy. The 5-year overall survival rates range between 24
and 43 %. Even though we solely present T4a carcinoma in
our series, we observed a 5-year overall survival for glottic
and supraglottic disease of 65.3 and 49.9 % being in favor
for TLM in treatment of advanced laryngeal carcinomas.
Therefore, the results achieved by TLM are comparable to
the outcome after conventional total laryngectomy while
having the advantage of organ preservation.
Primary (chemo)radiotherapy is associated with a high rate
of failure and the necessity of salvage therapy (mostly by total
laryngectomy). Different studies reported results in combi-
nation with neck dissection and total laryngectomy as salvage
treatment [14–16]. Local and loco-regional control rates range
from 43 to 65 %, disease-free survival rates are reported
between 40 and 68 %. Nonetheless, total laryngectomy was
necessary in up to 30 % of the cases. Patel et al. [17] compared
primary (chemo)radiotherapy with total laryngectomy in the
treatment of T4 laryngeal carcinoma. Of 34 included patients,
21 completed (chemo)radiotherapy and 13 underwent total
laryngectomy with postoperative (chemo)radiotherapy. After
(chemo)radiation 29 % revealed persistent/recurrent disease
at the primary site whereas no local recurrence occurred after
total laryngectomy. The authors conclude that although there
was a high initial complete response rate after primary
(chemo)radiotherapy, this response was not durable showing
a high local recurrence rate within 1 year.
The therapeutic concept of neoadjuvant chemotherapy
followed by radiation or surgery is still under clinical
evaluation [18–20]. Forastiere et al. [21] randomly
assigned 518 patients with locally advanced cancer of the
larynx to one of three treatments: induction of cisplatin
plus fluorouracil followed by radiotherapy, radiotherapy
with concurrent administration of cisplatin, or radiotherapy
alone. Eligibility for this study was based on the assertion
that alternative surgical treatment would be total laryn-
gectomy (stages III and IV). This makes a direct compar-
ison difficult, as there were many T2- and T3-category
tumors included that could have been treated by organ
preserving surgery (TLM/open). Moreover, high-volume
T4 carcinomas were excluded. Considering that the For-
astiere series is a positive selection compared to our study,
our 2-year laryngeal preservation of 86 % compares
favorably to 75 % in the induction cisplatin with radio-
therapy arm, 88 % in the concurrent chemoradiotherapy
arm and 70 % in the radiotherapy alone arm. Also the
2-year local control rate of 71 % in the present study
compared to 61, 78 and 56 % is in favor of TLM. Five-year
estimates of the Forastiere study [22] show a laryngec-
tomy-free survival of only 46.6 %, a loco-regional control
of 68.6 %, an overall survival rate of 55 %, and a disease-
free survival of 39 %. Compared to TLM, these 5-year
results are not convincing and therefore induction chemo-
therapy followed by radiation cannot be recommended for
locally advanced laryngeal carcinomas.
Regarding the concept of function preserving TLM for
cancer of the upper aerodigestive tract, the surgical,
oncological and functional principles do not differ from
those that are used in open surgical procedures. Complete
resection of the tumor is the main goal. However, pre-
serving healthy tissue and the anatomical integrity of the
larynx is an important benefit of TLM that is followed by
an improved quality of life. The technical limits of TLM
are reached when the tumor extents to the large vessels, or
if severe postoperative functional problems are to be
expected, mainly due to permanent aspiration.
After gaining experience with early stage cancers, the
indication for TLM has gradually been extended to T4
laryngeal tumors by the senior author in the early 1980s
Eur Arch Otorhinolaryngol (2013) 270:2719–2727 2725
123
[5]. Due to this expertise, numerous patients of the present
series were referred to our hospital with the hope of organ
preservation after being recommended total laryngectomy
elsewhere. Therefore, a selective referral of very advanced
tumors occurred and has to be considered when regarding
the oncologic results of our institution.
Iro et al. [23] reported the oncologic results of transoral
carbon dioxide laser microsurgery for 141 patients with
supraglottic carcinomas, thereof 33 presented with T4
carcinoma (all sites). Five-year recurrence-free survival
rates were 74.2 % for stage III and 45.3 % for stage IV.
Hinni et al. [24] treated advanced glottic and supraglottic
laryngeal cancer in 117 patients presenting with T2–T4
tumor, of these 33 patients with T4 carcinoma. Nineteen
patients received TLM alone with or without neck dissec-
tion, 14 additionally had adjuvant (chemo)radiotherapy.
Data for T4 patients only is not given. 5-year Kaplan–
Meier estimates for all patients were local control 74 %;
loco-regional control 68 %; disease-free survival 58 %;
and overall survival 55 %. 5-year laryngeal preservation
rate was 86 %. Rudert et al. [25]. investigated patients with
advanced supraglottic laryngeal carcinoma which were
treated with TLM. The achieved overall survival for T3
and T4 tumors was 47 %, however, data for T4 tumors
only are not given.
The results achieved by TLM are comparable to the
outcome after conventional total laryngectomy and supe-
rior to primary (chemo)radiotherapy. TLM with or without
radiotherapy therefore is a valid treatment strategy for
organ preservation. Furthermore, low morbidity and mor-
tality and excellent oncologic and functional outcomes
corroborate the importance of TLM as an attractive ther-
apeutic option in T4a laryngeal cancer.
When reviewing the published data on complications and
function, TLM shows advantages and validity as treatment
option. Postoperative bleeding requiring microlaryngo-
scopic treatment occurred in seven cases (9 %) and one
patient survived a cardiac complication intraoperatively.
Total rates of severe toxic effects reported by Forastiere
et al. [21] were 61 % (radiotherapy alone) and 81–82 % in
the two arms associated with chemotherapy. In addition, the
rate of patients being restricted to soft or liquid food
because of swallowing difficulties ranged from 9 to 23 %
after 1 year, depending on the therapy arm, and 14–16 %
after 2 years. It is not reported how many patients required a
temporary or permanent feeding tube. These figures are
significantly worse than those reported for laser surgery in
the present study or by other authors [23, 24] using TLM.
Regarding swallowing function, patients who undergo
TLM for cancer of the hypopharynx and larynx usually
have a good recovery of deglutition [26], which compares
favorably to open partial resection or (chemo)radiotherapy.
Even in our series of locally very advanced laryngeal
carcinoma, the functional results are good. Two patients
(3 %) required total laryngectomy because of aspiration, 2
(3 %) were treated for aspiration associated pneumonia and
4 (8 %) required a permanent gastrostomy or nasogastric
feeding tube. Furthermore, speech intelligibility after laser
microsurgery seems to be favorable when compared to
total laryngectomy even with voice prosthesis [27].
Conclusion
In selected patients with T4a squamous cell carcinoma of
the larynx TLM with or without radiotherapy can be a valid
option for organ preserving surgery. When compared to
other surgical and non-surgical treatment options, the rates
of organ and function preservation are very good and can
be achieved without compromising the oncological results
and with relatively low morbidity. Further benefits are the
possibility to integrate transoral laser surgery into any
therapeutic concept and the lack of necessary reconstruc-
tive surgery. These results are very satisfactory and
encouraging to continue and recommend TLM for
advanced laryngeal carcinoma, but as it is the data of only
one institution, results should be validated by prospective
multicenter studies.
Conflict of interest No conflict of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Hoffman HT, Karnell LH, Funk GF, Robinson RA, Menck HR
(1998) The National cancer data base report on cancer of the head
and neck. Arch Otolaryngol Head Neck Surg 124(9):951–962
2. Sikora AG, Toniolo P, DeLacure MD (2004) The changing
demographics of head and neck squamous cell carcinoma in the
United States. Laryngoscope 114(11):1915–1923. doi:10.1097/
01.mlg.0000147920.66486.bc
3. Strong MS, Jako GJ (1972) Laser surgery in the larynx. Early
clinical experience with continuous CO2 laser. Ann Otol Rhinol
Laryngol 81(6):791–798
4. Steiner W, Ambrosch P, Hess CF, Kron M (2001) Organ pres-
ervation by transoral laser microsurgery in piriform sinus carci-
noma. Otolaryngol Head Neck Surg 124(1):58–67. doi:S0194599
801661497
5. Steiner W (1993) Results of curative laser microsurgery of lar-
yngeal carcinomas. Am J Otolaryngol 14(2):116–121
6. Steiner W (1988) Experience in endoscopic laser surgery of
malignant tumours of the upper aero-digestive tract. Adv
Otorhinolaryngol 39:135–144
7. Canis M, Ihler F, Wolff HA, Christiansen H, Matthias C, Steiner
W (2012) Oncologic and functional results after transoral laser
microsurgery of tongue base carcinoma. Eur Arch Otorhinolar-
yngol. doi:10.1007/s00405-012-2097-1
2726 Eur Arch Otorhinolaryngol (2013) 270:2719–2727
123
8. Sobin LH, Compton CC (2010) TNM seventh edition: what’s
new, what’s changed: communication from the international
union against cancer and the American joint committee on can-
cer. Cancer 116(22):5336–5339. doi:10.1002/cncr.25537
9. Steiner W, Ambrosch P (2000) Endoscopic Laser Surgery of the
Upper Aerodigestive Tract. Thieme, Stuttgart, pp 100–104
10. Werner JA, Lippert BM, Schunke M, Rudert H (1995) Animal
experiment studies of laser effects on lymphatic vessels. A con-
tribution to the discussion of laser surgery segmental resection of
carcinomas. Laryngorhinootologie 74(12):748–755. doi:10.1055/
s-2007-997838
11. Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS,
Langer CJ, Ang KK, Gay G, Stewart A, Robinson RA (2006)
Laryngeal cancer in the United States: changes in demographics,
patterns of care, and survival. Laryngoscope 116(9 Pt 2 Suppl
111):1–13. doi:10.1097/01.mlg.0000236095.97947.26
12. Ampil FL, Nathan CO, Caldito G, Lian TF, Aarstad RF, Krish-
namsetty RM (2004) Total laryngectomy and postoperative
radiotherapy for T4 laryngeal cancer: a 14-year review. Am J
Otolaryngol 25(2):88–93. doi:S0196070903001595
13. Kada S, Hirano S, Tateya I, Kitamura M, Ishikawa S, Kanda T,
Asato R, Tanaka S, Ito J (2010) Ten years single institutional
experience of treatment for advanced laryngeal cancer in Kyoto
University. Acta Otolaryngol Suppl 563:68–73. doi:10.3109/0001
6489.2010.492237
14. Hinerman RW, Mendenhall WM, Amdur RJ, Stringer SP, Villaret
DB, Robbins KT (2002) Carcinoma of the supraglottic larynx:
treatment results with radiotherapy alone or with planned neck
dissection. Head Neck 24(5):456–467. doi:10.1002/hed.10069
15. Nakfoor BM, Spiro IJ, Wang CC, Martins P, Montgomery W,
Fabian R (1998) Results of accelerated radiotherapy for supraglottic
carcinoma: a Massachusetts general hospital and Massachusetts eye
and ear infirmary experience. Head Neck 20(5):379–384. doi:
10.1002/(SICI)1097-0347(199808)20:5\379:AID-HED4[3.0.CO;2-V
16. Haugen H, Johansson KA, Ejnell H, Edstrom S, Mercke C (2005)
Accelerated radiotherapy for advanced laryngeal cancer. Acta
Oncol 44(5):481–489. doi:10.1080/02841860510029950
17. Patel UA, Howell LK (2011) Local response to chemoradiation in
T4 larynx cancer with cartilage invasion. Laryngoscope 121(1):
106–110. doi:10.1002/lary.21181
18. (1991) Induction chemotherapy plus radiation compared with
surgery plus radiation in patients with advanced laryngeal cancer.
The Department of Veterans Affairs Laryngeal Cancer Study
Group. N Engl J Med 324(24):1685–1690. doi:10.1056/NEJM19
9106133242402
19. Laccourreye O, Brasnu D, Biacabe B, Hans S, Seckin S, Weinstein
G (1998) Neo-adjuvant chemotherapy and supracricoid partial lar-
yngectomy with cricohyoidopexy for advanced endolaryngeal
carcinoma classified as T3–T4: 5-year oncologic results. Head Neck
20(7):595–599. doi:10.1002/(SICI)1097-0347(199810)20:7\595:
AID-HED3[3.0.CO;2-K
20. Leon X, Quer M, Orus C, Lopez M, Gras JR, Vega M (2001)
Results of salvage surgery for local or regional recurrence after
larynx preservation with induction chemotherapy and radiother-
apy. Head Neck 23(9):733–738. doi:10.1002/hed.1104
21. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Mor-
rison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee
DJ, Leaf A, Ensley J, Cooper J (2003) Concurrent chemotherapy
and radiotherapy for organ preservation in advanced laryngeal
cancer. N Engl J Med 349(22):2091–2098. doi:10.1056/NEJMoa
031317349/22/2091
22. Forastiere AA, Maor A, Weber RS, Pajak TF, Glisson B, Trotti
A, Ridge JA, Ensley J, Chao C, Cooper J (2006) Long-term
results of Intergroup RTOG 91-11: a phase III trial to preserve the
larynx–Induction cisplatin/5-FU and radiation therapy versus
concurrent cisplatin and radiation therapy versus radiation ther-
apy. J Clin Oncol ASCO Ann Meet Proc Part I 24:5517
23. Iro H, Waldfahrer F, Altendorf-Hofmann A, Weidenbecher M,
Sauer R, Steiner W (1998) Transoral laser surgery of supraglottic
cancer: follow-up of 141 patients. Arch Otolaryngol Head Neck
Surg 124(11):1245–1250
24. Hinni ML, Salassa JR, Grant DG, Pearson BW, Hayden RE,
Martin A, Christiansen H, Haughey BH, Nussenbaum B, Steiner
W (2007) Transoral laser microsurgery for advanced laryngeal
cancer. Arch Otolaryngol Head Neck Surg 133(12):1198–1204.
doi:10.1001/archotol.133.12.1198
25. Rudert HH, Werner JA, Hoft S (1999) Transoral carbon dioxide
laser resection of supraglottic carcinoma. Ann Otol Rhinol Lar-
yngol 108(9):819–827
26. Bernal-Sprekelsen M, Vilaseca-Gonzalez I, Blanch-Alejandro JL
(2004) Predictive values for aspiration after endoscopic laser
resections of malignant tumors of the hypopharynx and larynx.
Head Neck 26(2):103–110. doi:10.1002/hed.10363
27. Olthoff A, Mrugalla S, Laskawi R, Frohlich M, Stuermer I, Kruse
E, Ambrosch P, Steiner W (2003) Assessment of irregular voices
after total and laser surgical partial laryngectomy. Arch Otolar-
yngol Head Neck Surg 129(9):994–999. doi:10.1001/archotol.
129.9.994129/9/994
Eur Arch Otorhinolaryngol (2013) 270:2719–2727 2727
123
